Before most JPMers arose Monday morning, Ipsen announced that it is buying rare disease biotech Albireo Pharma. That’s the second deal disclosed Monday morning, along with AstraZeneca grabbing cardiovascular upstart CinCor Pharma. With the Chiesi-Amryt rare disease deal from Sunday night, that’s three M&A announcements to kick off the annual healthcare investment banking conference, albeit […]

In its 41 years, the annual J.P. Morgan Healthcare Conference has borne witness to innumerable shifts and evolutions across the healthcare landscape, including the explosion of Big Pharma’s power—and, alongside it, an explosion in drug pricing—as well as the biotech booms that have occurred practically every decade since the 1980s. With that massive increase in […]

Philadelphia-based SFA Therapeutics has a big vision. The company, CEO and co-founder Ira Spector, Ph.D., tells BioBuzz, “wants to change the way medicine is practiced in the treatment of autoimmune disease.” Spector notes that the current standard-of-care approach to autoimmune diseases is immunosuppression, “to dumb down the symptoms,” which he says is like “treating a headache with a […]